Food And Drug Administration

Crucial research by Neil Osheroff and his lab leads to approval of the first new class of antibacterial drugs in decades. The drug, gepotidacin, developed by GlaxoSmithKline under the brand name Blujepa, will be available starting later this year, potentially bringing relief to thousands of women who struggle with uncomplicated urinary tract infections. Read More

In just over two years, a Vanderbilt-Neumora collaboration has led to the Phase 1 clinical trial of a treatment for schizophrenia spectrum disorders, which affect 3.7 million adults in the United States. This is the third chemical compound discovered at the Warren Center for Neuroscience Drug Discovery to reach Phase 1 clinical trials.     Read More

Neil Osheroff and his lab provide foundational research for new Urinary Tract Infection antibiotic. UTIs affect half of all women. Read More

Vanderbilt doctoral student Anup Challa, BE’21, MS’21, has been tapped to co-lead a team of researchers and patient advocates to identify areas across the world in need of health care for pregnant women and infants as the new chair of the Special Populations Coordinating Committee for the CURE Drug Repurposing Collaboratory. Read More

Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19. Read More